New care pathway aims to boost quality of life for long COVID sufferers
NCT ID NCT05787366
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a personalized health pathway for 400 people with persistent COVID-19 symptoms lasting more than 12 weeks. Participants receive nurse follow-up and can choose workshops on disease management, anxiety, and fatigue. The goal is to see if this approach improves quality of life over 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Personalized health pathway including nurse follow-up and workshops on disease management, anxiety, and fatigue
- What this could lead to
- If successful, this could provide an effective care model to improve quality of life for people with long COVID.
- What could go wrong
- This is a relatively small, non-randomized study without a control group, so results may not be conclusive or widely applicable. The intervention is complex and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Saint-Etienne
Saint-Etienne, 42055, France
-
DAC Loire
Saint-Etienne, 42100, France
-
Urps Medecins Libéraux Auvergne-Rhône-Alpes
Lyon, 69006, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?